Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Kidney Disease
73%
Core Outcome Set
73%
Clinical Trials
71%
Randomized Controlled Trial
49%
Meta-analysis
28%
Systematic Meta-analysis
28%
Sorafenib
24%
Risk Outcomes
24%
Patient Outcomes
24%
Risk-benefit
24%
Patient Benefit
24%
Drug Development
24%
Web-based Survey
24%
Clinical Perspective
24%
Patient Risk
24%
Sectional Analysis
24%
United States
24%
Osteoporosis
24%
Diverse Populations
24%
Pediatric Health
24%
Perinatology
24%
Reporting Guidelines
24%
Data Sharing Practices
24%
Addiction Research
24%
Data Sharing
24%
Geriatrics
24%
Gerontology
24%
Clinical Trial Registry
16%
Segmented Regression
12%
Health Outcomes
11%
FDA-approved Drugs
10%
Off-label Indications
10%
Literature Search
9%
Data Extraction
9%
Underrepresentation
9%
Race-ethnicity
9%
Trialists
8%
Addiction Medicine
8%
International Consortium
8%
Health Measurement
8%
Health-related Quality of Life
8%
Top 100
8%
Clinical Research
7%
Adverse Events
7%
Approved Indication
7%
Monotherapy
7%
Objective Response Rate
7%
Medicines Research
6%
Trial Strategy
6%
Policy Reform
6%
Medicine and Dentistry
Clinical Trial
100%
Chronic Kidney Disease
73%
Cross Sectional Study
73%
Randomized Controlled Trial
49%
Sorafenib
24%
Major Depressive Episode
24%
Perinatology
24%
Addiction Medicine
24%
Geriatrics
24%
Addictive Behavior
24%
Gerontology
24%
Logistic Regression Analysis
12%
Health Outcomes
11%
Quality of Life
11%
Adverse Event
10%
Decision Making
8%
Malignant Neoplasm
7%
Monotherapy
7%
Reproducibility
6%
Latent Class Analysis
6%
Cohort Studies
6%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
98%
Chronic Kidney Failure
73%
Drug Development
49%
Randomized Controlled Trial
49%
Sorafenib
49%
Cross Sectional Study
24%
Adverse Event
16%
Malignant Neoplasm
16%
Diseases
13%
Monotherapy
10%
Overall Survival
6%
Progression Free Survival
6%
Prevalence
6%